Pharma Adapts Ovarian Cancer Drugs Amid Genomics Revolution
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.
You may also be interested in...
Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.
Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
Endocyte is potentially propelled back to a Phase I company after its nearest commercial prospect flops and its collaboration with Merck is expected to disintegrate now that the drug missed PFS in ovarian cancer.
New PARP On The Block: BioMarin Starts Phase III, Could Prove To Be Best-In-Class
Class’s comeback gets more fuel at AACR/NCI/EORTC targeted therapies meeting. Evidence indicates BioMarin may have the most powerful PARP inhibitor, though AstraZeneca and Tesaro are slightly further in development.